Abstract
There are two major routes for clearance of aberrant cellular components: (i) the ubiquitin-proteasomal system (UPS); and (ii) the autophagy pathway. The UPS degrades individual abnormal proteins, whereas the autophagy pathway is the chief route for bulk degradation of large abnormal protein aggregates and aberrant organelles. Impairments of the protein degradation pathways are closely tied with many human diseases. Brain ischemia leads to protein misfolding and aggregation, resulting in overproduction of protein aggregate-associated organelles. Brain ischemia also damages protein degradation pathways. This chapter will discuss molecular mechanisms underlying the impairments of the UPS and autophagy pathways and how such impairments lead to multiple organelle failure and delayed neuronal death after brain ischemia.
Keywords: ubiquitin, microtubule-associated protein 1 light chain 3 (LC3), delayed neuronal death, autophagy, autophagosome, lysosome, protein aggregation, protein folding, organelle damage, global ischemia, focal ischemia
Current Drug Targets
Title: Protein Degradation Pathways after Brain Ischemia
Volume: 13 Issue: 2
Author(s): Pengfei Ge, Fan Zhang, Jingwei Zhao, Chunli Liu, Liankun Sun and Bingren Hu
Affiliation:
Keywords: ubiquitin, microtubule-associated protein 1 light chain 3 (LC3), delayed neuronal death, autophagy, autophagosome, lysosome, protein aggregation, protein folding, organelle damage, global ischemia, focal ischemia
Abstract: There are two major routes for clearance of aberrant cellular components: (i) the ubiquitin-proteasomal system (UPS); and (ii) the autophagy pathway. The UPS degrades individual abnormal proteins, whereas the autophagy pathway is the chief route for bulk degradation of large abnormal protein aggregates and aberrant organelles. Impairments of the protein degradation pathways are closely tied with many human diseases. Brain ischemia leads to protein misfolding and aggregation, resulting in overproduction of protein aggregate-associated organelles. Brain ischemia also damages protein degradation pathways. This chapter will discuss molecular mechanisms underlying the impairments of the UPS and autophagy pathways and how such impairments lead to multiple organelle failure and delayed neuronal death after brain ischemia.
Export Options
About this article
Cite this article as:
Ge Pengfei, Zhang Fan, Zhao Jingwei, Liu Chunli, Sun Liankun and Hu Bingren, Protein Degradation Pathways after Brain Ischemia, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201694
DOI https://dx.doi.org/10.2174/138945012799201694 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Nanomedical Platform for Drug Delivery in Cancer
Current Organic Chemistry Functional Genomics Approaches in Cancer Research
Current Genomics Ion Transporters in Brain Tumors
Current Medicinal Chemistry miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry SALL4: Engine of Cell Stemness
Current Gene Therapy Chemical Composition and Biological Activities of <i>Croton delpyi, Croton decalvatus</i> and <i>Croton caudatus</i>
The Natural Products Journal Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery